Spotlight on Rasagiline in Parkinson's Disease

Author： Oldfield Vicki   Keating Gillian M.   Perry Caroline M.  

Publisher： Adis International

ISSN： 1172-7047

Source： CNS Drugs, Vol.22, Iss.1, 2008-01, pp. : 83-86

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Rasagiline meta-analysis: a spotlight on clinical safety and adverse events when treating Parkinson's disease

By Solís-García del Pozo Julián   Mínguez-Mínguez Sara  

Expert Opinion on Drug Safety, Vol. 12, Iss. 4, 2013-07 ,pp. : 479-486

Informa Healthcare

Access to resources Recommend Favorite

Safety of rasagiline for the treatment of Parkinson's disease

By Perez-Lloret Santiago   Rascol Olivier  

Expert Opinion on Drug Safety, Vol. 10, Iss. 4, 2011-07 ,pp. : 633-643

Informa Healthcare

Access to resources Recommend Favorite

Spotlight on Rotigotine in Parkinson's Disease

By Baldwin Claudine M.   Keating Gillian M.  

Drugs & Aging, Vol. 25, Iss. 2, 2008-01 ,pp. : 175-177

Adis International

Access to resources Recommend Favorite

Rasagiline in the pharmacotherapy of Parkinson’s disease – a review

By Rascol Olivier  

Expert Opinion on Pharmacotherapy, Vol. 6, Iss. 12, 2005-10 ,pp. : 2061-2075

Informa Healthcare

Access to resources Recommend Favorite

Rasagiline monotherapy beneficial in early Parkinson's disease

By  

Inpharma, Vol. 1, Iss. 1373, 2003-01 ,pp. : 8-8

Adis International

Access to resources Recommend Favorite